What is LBRX's gain/loss on asset sales?

LBRX (LBRX) reported gain/loss on asset sales of $0 in Q1 2026.

What does gain/loss on asset sales mean?

Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.

LBRX LBRX Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

MapLight Therapeutics, Inc. MPLT

-$4K-129%

Alto NeuroscienceANRO

-$9K+78.0%

Zevra Therapeutics, Inc.ZVRA

$43.31M—

Opko HealthOPK

$34K-99.1%

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+163%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfInvestments.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's gain/loss on asset sales?: LBRX (LBRX) reported gain/loss on asset sales of $0 in Q1 2026.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.